Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8446269 | 0.91 | MEP1B (0.58) | MEP1BALDH1A1PKMMAPTMMP1 | |
| SCHEMBL6324179 | 0.87 | MEP1B (0.67) | MEP1BALDH1A1PKMMMP1GAA | |
| SCHEMBL7383813 | 0.87 | ALDH1A1 (0.71) | MEP1BALDH1A1PKMMMP1GAA | |
| SCHEMBL4824911 | 0.87 | HSD17B10 (0.67) | ALDH1A1MAPTGAAMMP2MMP9 | |
| SCHEMBL8425825 | 0.84 | MAPT (0.60) | MEP1BALDH1A1MAPTPOLBNPSR1 | |
| SCHEMBL2945763 | 0.84 | ALDH1A1 (0.69) | MEP1BALDH1A1PKMMAPTGAA | |
| SCHEMBL7410575 | 0.84 | MEP1B (0.91) | MEP1BMMP1MMP12MMP2MMP9 | |
| SCHEMBL25202175 | 0.83 | F3 (0.63) | MEP1BALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL4832503 | 0.83 | MEP1B (0.49) | MEP1BALDH1A1PKMMAPTMMP1 | |
| SCHEMBL7674957 | 0.82 | GAA (0.59) | MEP1BALDH1A1PKMMAPTMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383535-B2 | Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-08-12 | — | — | US | disclosed |
| CN-117623996-A | Bivalent KEAP1-NRF2 inhibitor, preparation method and medical application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20220401419-A1 | HYDROGEN PEROXIDE-RESPONSIVE KEAP1-NRF2 PPI INHIBITOR PRODRUG, AND PREPARATION METHOD THEREFOR | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-112367983-A | 1,4 substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction | 伊利诺伊大学评议会 | 2021-02-12 | — | — | CN | disclosed |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401419-A1 | HYDROGEN PEROXIDE-RESPONSIVE KEAP1-NRF2 PPI INHIBITOR PRODRUG, AND PREPARATION METHOD THEREFOR | KEAP1, NFE2L2, HMOX1 | MEP1B 3949/4885ALDH1A1 843/4885PKM 859/4885 |
| US-12383535-B2 | Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor | KEAP1, NFE2L2, HMOX1 | MEP1B 3949/4885ALDH1A1 843/4885PKM 859/4885 |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | MEP1B 3750/4885ALDH1A1 4832/4885PKM 3645/4885 |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | MEP1B 34/4885ALDH1A1 3336/4885PKM 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.